Background. Polymorphisms in CYP2B6 affect the steady-state plasma concentrations of nevirapine and efavirenz. In many resource-limited countries, a single dose of nevirapine has been widely prescribed to pregnant women at delivery, to reduce mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1). We characterized associations between genetic polymorphisms and the pharmacokinetics of single doses of nevirapine and efavirenz.
The nonnucleoside reverse-transcriptase inhibitors (NNRTIs) nevirapine and efavirenz are widely prescribed in multiple-drug regimens for the treatment of HIV-1 infection. Both drugs have long plasma half-lives [1, 2] and low barriers to viral genetic resistance, such that a single mutation in HIV-1 reverse transcriptase confers resistance [2] . Whereas use of efavirenz is strongly discouraged during the first trimester of pregnancy because of potential harm to the fetus [3] , nevirapine is extensively used during pregnancy to prevent mother-to-child transmission of HIV-1. In resourcelimited countries, this typically involves administration of a single 200-mg oral dose of nevirapine to the mother at the time of delivery, with or without additional antiretroviral agents [4] . Unfortunately, because of the long half-life of nevirapine, a low genetic barrier to resistance, and the rapid mutability of HIV-1 [5] , even a single dose of nevirapine, if given as monotherapy, can select for NNRTI-resistant virus in the mother [6 -8] . This compromises the efficacy of subsequent multiple-drug regimens containing NNRTI, particularly when they are initiated within 6 months after administration of the single dose [9 -11] .
There is considerable interindividual variability in the disposition of antiretroviral agents, at least some of which is caused by polymorphisms in drug-metabolism genes. Both nevirapine and efavirenz are metabolized primarily by cytochrome (CYP) P450 2B6 [12] [13] [14] . A frequent CYP2B6 variant (516G3 T) predicts decreased plasma clearance of efavirenz and increased plasma efavirenz exposure at steady state [15] [16] [17] . A less frequent CYP2B6 polymorphism, 983C3 T, also predicts increased plasma efavirenz exposure of a similar magnitude (although data are scant for 983 CC homozygosity) [18 -20] . More recent data establish that CYP2B6 516G3 T and 983T3 C are also associated with increased steady-state plasma nevirapine exposure [17, 21, 22] . Both CYP2B6 516T and 983C are more frequent among individuals of African ancestry than among white individuals [15, 16] .
The present study characterized associations between genetic polymorphisms and the plasma pharmacokinetics of nevirapine and efavirenz after administration of single doses to healthy, nonpregnant, HIV-negative African Americans.
SUBJECTS, MATERIALS, AND METHODS
Study subjects and design. The present study enrolled African Americans solely on the basis of self-reported identity. Eligible study participants were healthy and had acceptable findings of screening hematologic tests and chemical analyses, negative HIV serologic findings, and undetectable plasma HIV-1 RNA. Women of childbearing potential had negative pregnancy test results. Criteria for exclusion from the study included the use of medications known or predicted to interact with hepatic CYP P450 isoforms. Human experimentation guidelines of the US Department of Health and Human Services were followed in the conduct of this research. All work was conducted in accordance with the Declaration of Helsinki. The study was approved by the Vanderbilt University institutional review board, and all participants provided written, informed consent.
On day 0, each participant received a single 200-mg oral dose of nevirapine; serial sampling to determine pharmacokinetics then ensued. At least 3 weeks after receiving nevirapine, each participant then received a single 600-mg oral dose of efavirenz, which was followed by serial sampling to determine pharmacokinetics. Study drugs were administered by study personnel. The study was performed in the Vanderbilt General Clinic Research Center.
Drug assays. Plasma samples for drug assays were obtained at 0.5, 1, 2, 4, 6, 8, and 12 h after administration of each dose, as well as on days 1 (i.e., at 24 h), 2, 3, 5, 7, 9, and 13. Plasma was separated by centrifugation at 4°C and was stored at Ϫ80°C. Nevirapine and efavirenz were quantified in the laboratory of Dr. Grant Wilkinson, with liquid-liquid extraction performed using cyclohexane and followed by isocratic high-performance liquid chromatography. In each assay, a 0.5-mL aliquot of plasma was spiked with a 10 g/mL solution of carbamazepine in MeOH, which was used as the internal standard (for efavirenz, 50 L; for nevirapine, 40 L). To this was added 500 L of saturated sodium borate (pH ϳ9.5). Liquid-liquid extraction was achieved by shaking the sample for 15 min with 6 mL of cyclohexane. The samples then underwent centrifugation for 10 min, and the upper organic layer separated and was dried down at 40°C under a stream of nitrogen. The residue was reconstituted in 200 L of mobile phase, and 50 L of the extract was injected into a 5-m Ultrasphere C18 column (25 cm ϫ 4.6 mm; Beckman Coulter) attached to a Brownlee C18 guard cartridge.
The mobile phase used to assay efavirenz was a mixture of water, acetonitrile, and diethylamine (65/35/0.2, v/v/v). The flow rate was maintained at 1.1 mL/min, and UV detection of the peaks for efavirenz and carbamazepine was achieved at 269 nm in a run time of ϳ11 min. For nevirapine, a mobile phase of water and acetonitrile (70/30, v/v) at a flow rate of 1 mL/min was used, and UV detection of peaks for nevirapine and carbamazepine was achieved at 215 nm in a run time of ϳ16 min. Assays were linear over a concentration range of 50 -5000 ng/mL. For the efavirenz method, the r 2 value for calibration curves ranged from 0.9911 to 0.9994 (mean, 0.9970). For the nevirapine method, the r 2 for calibration curves ranged from 0.9918 to 0.9998 (mean, 0.9970). The coefficient of variation (CV) for nevirapine and efavirenz in the assay range of 500 -3000 ng/mL ranged from 4.1% to 11.8%.
Estimates of pharmacokinetic parameters. Estimates of pharmacokinetic parameters were determined using a noncompartmental approach (WinNonlin software, version 4.01; Pharsight). The parameters calculated were the area under the curve (AUC), the maximum plasma concentration (C max ), the time to C max (T max ), oral clearance (CL/F), terminal apparent distribution volume (V z /F), and elimination half-life (t 1/ 2 ). The terminal elimination t 1/ 2 was based on the slope of the regression line through at least the final 3 concentration-time points. The AUC value was determined using the linear/log trapezoidal method. C max and T max values were obtained directly from the observed concentration-time data. The CL/F was calculated as the dose divided by the AUC value. The V z /F was calculated as the dose divided by the product of the elimination rate constant ( z ) and the AUC value. The t 1/ 2 was calculated as ln(2)/ z . Pharmacokinetic parameters were determined by E.P.A., who was blinded to the genotyping results. Protein binding-corrected 95% inhibitory concentration (IC 95 ) values for nevirapine and efavirenz were provided by Monogram Bioscience.
Statistical methods. Pharmacokinetic parameters are presented as median values and interquartile ranges (IQRs). Body mass index (BMI) was calculated as the body weight in kilograms divided by the square of the height in meters. The Spearman correlation coefficient () was used to assess dose-response trends in bivariate associations between continuous variables and genotype, as well as to determine the directionality of such associations. For CYP2B6 516/983, the genotype was coded as an ordered continuous variable, with "1" denoting an extensive metabolizer; "2," an intermediate metabolizer; and "3," a slow metabolizer. For other exploratory polymorphism analyses, "1" denoted homozygous; "2," heterozygous; and "3," the other homozygous genotype, which was ordered as A Ͻ C Ͻ G Ͻ T.
Multiple linear regression models were used to test for effects of trend based on genotype as an ordered continuous variable and on pharmacokinetic response parameters adjusted for BMI and sex. For all multivariable models, regression residuals were examined graphically, and sensitivity analysis was conducted using Box-Cox transformations of pharmacokinetic response variables to achieve normality of the residuals. Results were similar for analyses with untransformed outcome variables. Results from untransformed models are presented. All reported P values are unadjusted for multiple tests. All analyses used a 5% 2-sided significance level and were performed using R software (version 2.6.2) [23] and SAS software (version 9.1; SAS). Linkage disequilibrium (LD) plots and values were generated using Haploview [24] . Hardy-Weinberg equilibrium was assessed using exact tests [25] .
Characterization of human genetic variants. Genomic DNA was extracted from whole blood. Genotyping of polymorphisms of primary interest (CYP2B6 516G3 T [CYP2B6*6] and 983T3 C [CYP2B6*18]) was accomplished using the ABI Prism 7900 HT Sequence Detection System (Applied Biosystems). TaqMan assays were used to genotype the CYP2B6 polymorphisms 516G3 T (rs3745274; assay ID C_7817765_60) and 983T3 C (rs28399499; assay ID C_60732328_10). Assay performance for the genotyping of CYP2B6 516G3 T was improved by the digestion of genomic DNA with XhoI before assay. Data were analyzed using ABI Sequence Detection System software (version 2.1; Applied Biosystem).
Composite CYP2B6 genotypes, which were based on reported associations with steady-state efavirenz pharmacokinetics [18 -20] , were assigned as follows: "extensive metabolizer" denoted no variant allele at either position 516 or 983; "intermediate metabolizer," a single variant allele at either position 516 or 983, but not both; "slow metabolizer," 2 variant alleles (i.e., either 516 TT, 983 CC, or 516 GT with 983 TC). For exploratory analyses, an additional 51 polymorphisms (46 in CYP2B6, 3 in ABCB1, 1 in CYP3A4, and 1 in CYP3A5) were assayed using MassARRAY iPLEX Gold (Sequenom).
Our strategy for the CYP2B6 Sequenom assay design was as follows. We tagged the entire CYP2B6 gene by use of SeattleSNPs [26] , including 5 kb in each 5' and 3' untranslated region (UTR), using a cosmopolitan strategy across populations (Yoruba, Asian, African-American, European American, and Hispanic), with a 5% allelic frequency cutoff, a threshold of 0.80 for r 2 , 85% data convergence for tagging polymorphisms, and 70% data convergence for clustering. Additional polymorphisms that were of interest (but were not extremely infrequent) were added based on reports published elsewhere [19, 20] . We also added polymorphisms with at least 5% allelic frequency in 20 kb of the 5' UTR identified using the Ensembl Genome Browser [27] , as well as upstream polymorphisms possibly associated with CYP2B6 expression, on the basis of a report published elsewhere [28] . (The final Sequenom assay design available upon request.) Genotypes were confirmed by visual inspection of plots. Laboratory personnel with no knowledge of clinical data performed the genotyping. All assays were run in duplicate and were in complete agreement. No individual was excluded from participation on the basis of genotype. (table 1 , which appears only in the electronic version of the Journal). On the basis of the composite CYP2B6 516G3 T and 983T3 C genotype (hereafter referred to as the "CYP2B6 516/ 983" genotype), 7 individuals were predicted to be slow metabolizers (5 were homozygous for CYP2B6 516 TT and 2 were heterozygous for both 516 GT and 983 TC). No individuals were homozygous for CYP2B6 983 CC. Seventeen were predicted to be intermediate metabolizers, of whom 16 (94%) were heterozygous for CYP2B6 516 GT. Genotype groups did not differ significantly according to the age, sex, or BMI.
RESULTS

Characteristics
Pharmacokinetics of nevirapine. The plasma concentrationtime profiles for nevirapine are presented in figure 1. There was considerable interindividual variability in plasma nevirapine exposure over the 13 days after administration of a single 200-mg dose. In all participants, concentrations exceeded the nevirapine protein binding-corrected IC 95 for wild-type HIV-1 (196.6 ng/mL) for at least 5 days. For all study participants, summary data on the pharmacokinetics of nevirapine, according to CYP2B6 516/983 genotype, are presented in table 2. There was no significant association between the CYP2B6 516/983 genotype and 312-h AUC (AUC 0 -312h ), clearance, C max , t 1/ 2 , or V z /F of nevirapine. To assess the duration of selective pressure for drug resistance that would be exerted on wild-type HIV-1, we calculated the times until the plasma level of nevirapine would decrease to the protein binding-corrected IC 95 for nevirapine. Again, the CYP2B6 516/983 genotype did not predict a difference in the time above the protein binding-corrected IC 95 . Similarly, in analyses involving CYP2B6 516G3 T and 983T3 C separately, there were no significant associations with the pharmacokinetics of nevirapine (data not shown). BMI was inversely correlated with the C max of nevirapine ( ϭ -0.64; P Ͻ .0001), but it did not correlate significantly with the clearance, t 1/ 2 , AUC 0 -312h , or V z /F of nevirapine (data not shown). In multivariable analyses that adjusted for BMI and sex, there were still no associations between the CYP2B6 516/983 genotype and pharmacokinetic parameters (table 2) .
Pharmacokinetics of efavirenz. The plasma concentrationtime profiles for efavirenz among all study participants are presented in figure 1. There was considerable interindividual variability in plasma efavirenz exposure over the 13 days after administration of a single 600-mg dose. In all but one participant, concentrations exceeded the efavirenz protein bindingcorrected IC 95 (54.7 ng/mL) for at least 5 days.
For all study participants, summary data on the pharmacokinetics of efavirenz, according to CYP2B6 516/983 genotype, are presented in table 2. In contrast to nevirapine, the CYP2B6 genotype was associated with the pharmacokinetics of efavirenz. There was an association between the CYP2B6 516/983 genotype and plasma clearance of efavirenz, the AUC 0 -312h value, and the V z /F, but not with the time needed for the plasma concentration to decrease to the protein binding-corrected IC 95 for efavirenz or the t 1/ 2 or C max of efavirenz. In analyses involving each polymorphism separately, there was a significant association of CYP2B6 516G3 T with the efavirenz AUC 0 -312h ( ϭ 0.45; P ϭ .008) and with efavirenz clearance ( ϭ -0.39; P ϭ .026). There were no other statistically significant associations with CYP2B6 516G3 T.
BMI was positively correlated with efavirenz clearance ( ϭ 0.49; P ϭ .0043) and V z /F ( ϭ 0.48; P ϭ .0058), and it was inversely correlated with the AUC 0 -312h value ( ϭ -0.50; P ϭ .0025). BMI did not correlate with the efavirenz t 1/ 2 , C max , or time to IC 95 (data not shown). In multivariable analyses that adjusted for BMI and sex, the CYP2B6 516/983 genotype remained significantly associated with efavirenz plasma clearance and the AUC 0 -312h value (table 2) .
Additional genetic polymorphisms. The lack of association between the CYP2B6 516/983 genotype and the pharmacokinetics of nevirapine was unexpected. We therefore expanded genotyping to include 51 additional polymorphisms (46 in CYP2B6, 3 in ABCB1, 1 in CYP3A4, and 1 in CYP3A5) listed in table 1 (which appears only in the electronic version of the Journal). All polymorphisms were in Hardy-Weinberg equilibrium (P Ͼ .05). There were no variant alleles detected for rs34619327. A linkage disequilibrium (LD) plot for CYP2B6 polymorphisms is provided in figure 2 . Associations between polymorphisms and pharmacokinetic parameters for nevirapine are shown in table 3. In these exploratory analyses, which are uncorrected for multiple comparisons, 12 CYP2B6 polymorphisms were associated with at least one nevirapine pharmacokinetic parameter ( Ͼ 0.3 or Ͻ -0.3). These included five 5' UTR and 7 intronic polymorphisms, only one of which (rs892216) was in LD with CYP2B6 516G3 T at r 2 Ͼ 0.6 ( figure  2 and table 3 ). There was no association between any polymorphism and BMI, and no ABCB1, CYP3A4, or CYP3A5 polymorphism was associated with the pharmacokinetic parameters of nevirapine.
We similarly explored associations with pharmacokinetic parameters for efavirenz (table 3). In these exploratory analyses, 24 CYP2B6 polymorphisms in addition to 516G3 T were associated with at least one efavirenz pharmacokinetic parameter ( Ͼ 0.3 or Ͻ -0.3), 9 of which were in LD with 516G3 T at r 2 Ͼ 0.6 ( figure 2 and table 3 ). Among genes other than CYP2B6, only a CYP3A5 polymorphism was associated with a single efavirenz pharmacokinetic parameter (V z /F).
Six CYP2B6 polymorphisms were concordantly correlated with AUC 0 -312h and/or clearance values for both nevirapine and efavirenz ( Ͼ 0.3 or Ͻ -0.3), 12 were correlated for efavirenz but not nevirapine, and 4 were correlated for nevirapine but not efavirenz (table 3) .
Intraindividual associations between nevirapine and efavirenz pharmacokinetics. The present study provided a unique opportunity to assess intrasubject associations between nevirapine and efavirenz pharmacokinetics. There were significant correlations between AUC 0 -312h values for nevirapine and efavirenz ( ϭ 0.50; P ϭ .0027) and between clearance values ( ϭ 0.37; P ϭ .0396). There were no other significant correlations between corresponding pharmacokinetic parameters (figure 3).
Safety and tolerability. The study participants tolerated the study medications without difficulty. There were no adverse events of grade 2 or greater, and no study participant experienced rash.
DISCUSSION
Single doses of nevirapine have been widely prescribed to pregnant women in resource-limited countries, to reduce motherto-child transmission of HIV-1 [4] . The most important finding of the present study is that frequent, functional CYP2B6 polymorphisms (516G3 T and 983T3 C) did not predict substantial differences in plasma drug exposure after administration of a single 200-mg dose of nevirapine to nonpregnant, HIV-negative volunteers. This finding is contrary to our expectation that CYP2B6 slow metabolizer genotypes would predict delayed nevirapine clearance and increased nevirapine exposure after administration of a single 200-mg dose. We based this expectation on the major role of CYP2B6 in nevirapine metabolism [12, 13] and on reports that CYP2B6 516G3 T and 983T3 C were associated with increased steady-state nevirapine exposure among HIV-infected individuals [17, 21, 22] . We readily demonstrated associations between the CYP2B6 516/983 genotype, delayed plasma efavirenz clearance, and increased plasma efavirenz exposure after administration of a single 600-mg dose of efavirenz. This association with efavirenz was also expected based on previous reports describing steady-state efavirenz exposure [15] [16] [17] [18] [19] . In the present study, the clear association between the CYP2B6 516/983 genotype and efavirenz pharmacokinetic parameters suggests that substantial associations with nevirapine pharmacokinetics, if present, should have been seen in these same individuals.
There are several possible explanations for the lack of association between the pharmacokinetics of single-dose nevirapine and the CYP2B6 516/983 genotype. Variants other than CYP2B6 516G3 T and 983T3 C might better describe pharmacokinetic variability after administration of single-dose nevirapine. In this regard, exploratory analyses involving 51 additional polymorphisms in CYP2B6, ABCB1, CYP3A4, and CYP3A5 suggested possible associations between nevirapine pharmacokinetic parameters and additional CYP2B6 polymorphisms, only one of which was in LD with CYP2B6 516G3 T. However, unless replicated in other studies, these latter associations must be considered to be hypothesis generating and, possibly, the consequence of multiple comparisons [29] . We must emphasize that additional secondary pathways for nevirapine metabolism, such as CYP3A [12, 13] , may minimize the influence of CYP2B6 variants, whereas efavirenz is more exclusively metabolized through CYP2B6 [14] . This is consistent with the observation that the fold increase in drug concentration associated with CYP2B6 variants at steady state in HIV-positive individuals appears to be less for nevirapine [17, 21] than for efavirenz [15] [16] [17] [18] [19] . In addition, nevirapine metabolism undergoes considerable autoinduction [12, 30] . Differences that are not apparent after administration of a single dose may become apparent with repeated dosing.
The present study has implications for the global epidemiologic profile of HIV drug resistance. A single dose of nevirapine administered at delivery, followed by a single dose of nevirapine given to the newborn, reduces intrapartum vertical transmission by ϳ3-fold. Unfortunately, a single dose can select for drugresistant virus, which compromises the response of the mother to subsequent regimens containing NNRTIs [9, 10] . Intraindividual variability in the plasma clearance of nevirapine in this setting will affect selective pressure for drug-resistant HIV-1. A report from Côte d'Ivoire showed that, among 63 HIV-infected women, a higher median plasma concentration of nevirapine in the mother at 48 h post partum was associated with an increased likelihood of detection of nevirapine-resistant virus in the mother at 4 weeks post partum [31] . Delayed nevirapine clearance associated with the CYP2B6 genotype would have identified a genetically defined slow metabolizer population at increased risk for HIV-1 resistance. In addition, because CYP2B6 slow metabolizer genotypes are most frequent among individuals of Af- rican ancestry [15, 16] , the influence would have disproportionately affected sub-Saharan Africa. There has been controversy regarding the relative merits of single-dose nevirapine (see [11] ). The present study suggests that the CYP2B6 516/983 genotype need not fuel this controversy. The other candidate CYP2B6 polymorphisms suggested by our exploratory analyses warrant replication testing in other cohorts. Our findings do not negate the detrimental influence of single-dose monotherapy nevirapine on viral drug resistance but, rather, reinforce the need for more contemporary regimens to prevent vertical transmission.
It has been suggested that, among patients who have virologic control while receiving regimens containing efavirenz and who then discontinue all drugs in the regimen, CYP2B6 516G3 T will predict more prolonged drug exposure and selective pressure for drug-resistant HIV-1. The primary evidence for this, however, comes largely from modeling of steady-state data during treatment among individuals who did not discontinue therapy [32] . The present study provides empirical support for this concept. The relevance of associations between the additional CYP2B6 polymorphisms identified herein, only some of which are in LD with CYP2B6 516G3 T, and efavirenz metabolism is uncertain. As with nevirapine, these associations must be considered spurious unless they are replicated in other studies [29] . There were limitations to the present study. A larger sample size would have allowed a more precise definition of associations between CYP2B6 and pharmacokinetics. In addition, we did not study pregnant individuals, for whom single-dose nevirapine is most relevant. Pregnancy can alter drug metabolism through effects on V z /F, gastric motility, and hepatic drug metabolism. In a previous study involving 9 pregnant women who received a single 200-mg dose of nevirapine at 38 weeks gestation, followed by 72-h pharmacokinetic sampling [33] , the median C max (1865 ng/mL) was comparable to that noted in the present study (1682 ng/mL), whereas median oral clearance was more rapid (24.9 mL/kg/h and 17.6 mL/kg/h, respectively). Nevirapine exposure in the present study may have been somewhat greater than that among 110 postpartum Thai women studied by sparse sampling [34] . We studied only African Americans, and it is conceivable that genetic predictors of nevirapine pharmacokinetics will differ in other populations. In this regard, nevirapine elimination in the present study may have been somewhat slower than that noted among 44 nonpregnant Dutch women (median t 1/ 2 , 56.7 h; range, 25.6 -164.1 h) [35] . We cannot exclude the possibility that CYP induction by nevirapine had some effect on subsequent efavirenz pharmacokinetic profiles. In addition, genetic associations identified with single doses may differ at steady state. Because we did not correct for multiple comparisons, many (if not all) of these novel associations may be spurious. Finally, although we characterized many CYP2B6 polymorphisms, we cannot exclude an effect of additional polymorphisms in CYP2B6 and/or other genes on nevirapine metabolism.
The AIDS pandemic is an immense challenge. Improved knowledge of associations between human genetic variants and treatment responses may ultimately improve HIV treatment strategies for individuals and populations. The present study advances our understanding of the influence of human genetic variants among individuals who receive single doses of NNRTIs. Table 1 . Genotype data for all genetic polymorphisms assessed by primary and exploratory analyses.
